Drug Modalities
Technical Solutions
ESG
Newsroom
About Us
CN
Home/Newsroom/News

News 2024-10-01

Porton Newsletter | Q3 2024 Recap

Biologics and Conjugates CDMO Services
Tides CDMO Services
Porton J-STAR Cutting-Edge Technologies

Others
More
peptide CDMO

News 2026-03-22

Porton and Jianxiang Forge Strategic Partnership to Build a New High Ground for Large-scale Peptide Drug Manufacturing

Porton and Jianxiang partner to deliver integrated peptide CDMO services from development to commercial manufacturing, offering scalable, compliant solutions for global clients.
Daewoong

News 2026-03-03

Porton Wins “2025 Best CRO” Award from Daewoong Pharma

Daewoong Pharma highly recognized Porton’s contributions to its drug development through active cooperation based on Porton’s excellent capabilities and expertise.
Become part of Porton's community to access personalized insights and resources.
Subscribe for the Newsletter
Porton requires your contact information to reach out to you about our products and services. You can unsubscribe from these communications at any time. For details on how to unsubscribe and our commitment to protecting your privacy, please review our Legal Disclaimer Terms and Porton Privacy.
US: (609) 860-1300
CN: (86) 23-8608-3200

ⓒ 2025 PORTON Legal Notices | Porton Privacy

This website provides information on products tailored for a diverse audience and may include product details or information that are not readily accessible or valid in your country. Please note that we do not accept any responsibility for accessing such information in a manner that may violate any legal processes, regulations, registrations, or usage guidelines in your country of origin.

Become part of Porton's community to access personalized insights and resources.
Submit
By clicking “Submit” you agree to our Legal Disclaimer terms and conditions and the Porton Privacy and Cookies Policy.

ⓒ 2025 PORTON Legal Notices | Porton Privacy

US: (609) 860-1300
CN: (86) 23-8608-3200